The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Omega Therapeutics's share price is $0.003.
Omega Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.15. Hence, Omega Therapeutics's PS Ratio for today is 0.02.
The historical rank and industry rank for Omega Therapeutics's PS Ratio or its related term are showing as below:
OMGAQ's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.515 * Ranked among companies with meaningful PS Ratio only.
Omega Therapeutics (OTCPK:OMGAQ) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Omega Therapeutics PS Ratio Related Terms
Omega Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Omega Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Omega Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Omega Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Omega Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Omega Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Omega Therapeutics's Share Price of today is $0.003. Omega Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.15.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Omega Therapeutics (OMGAQ) has a PS Ratio of 0.02 as of Jul. 11, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Omega Therapeutics and its competitors.
Is Omega Therapeutics' PS Ratio too high?
Omega Therapeutics' current PS Ratio is 0.02. The Biotechnology industry median PS Ratio is 9.52. Omega Therapeutics' value of 0.02 is 99.8% below this industry median. Overall, Omega Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Omega Therapeutics' PS Ratio compare to ENDV and ORGS?
Omega Therapeutics' PS Ratio of 0.02 can be compared against companies in the Biotechnology industry. The industry median PS Ratio is 9.52. Omega Therapeutics' value of 0.02 is 99.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.52, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Omega Therapeutics's current PS Ratio of 0.02 is 99.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Omega Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Omega Therapeutics's current PS Ratio is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omega Therapeutics stock overvalued right now?
Omega Therapeutics (OMGAQ) has a current PS Ratio of 0.02. The current PS Ratio is 0.02 and 99.8% below the Biotechnology industry median of 9.52. Omega Therapeutics' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Omega Therapeutics (OMGAQ), the current PS Ratio is 0.02 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.
16GF Score
Get the complete analysis for OMGAQ
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OMGAQ has been successfully added to your 
